• Korean Journal of Biological Psychiatry
• /
• v.3 no.1
• /
• pp.83-87
• /
• 1996

The effects of disulfiram implantation therapy have three components : placebo, pharmacological, and psychological effects, However, considering the fact that there is no reported DER(disulfiram-ethanol reaction) in placebo implanted patients and the absorption of implanted disulfiram is not sufficient to produce DER, the major effect of disulfiram implantation is psychological rather than placebo and pharmacological one, Recently, there have been great efforts to develop a new farm of disulfiram which could exert a real pharmacological effect through the heightened bioavailability, To illustrate several examples, there are copolymer consisting of disulfiram and polymer such as polyethylene glycol and PLGA(polyglycolic-co-L-lactic acid) and depot in which disulfiram is dissolved into saline solution containing 5% w/v carboxymethylcellulose or 0.1% polysorbate 80. On the other hand, there has been a continuous research about Me-DTC, an active metabolite of disulfiram, which inhibit ALDH (acetaldehyde dehydrogenase) more potently even at a smaller amount than disulfiram. In the future. In is hoped to develop a new form of disulfiram with high bioavailability at a small amount.

• Genomics & Informatics
• /
• v.12 no.4
• /
• pp.151-155
• /
• 2014

In November 2013, the US Food and Drug Administration (FDA) sent a warning letter to 23andMe, Inc. and ordered the company to discontinue marketing of the 23andMe Personal Genome Service (PGS) until it receives FDA marketing authorization for the device. The FDA considers the PGS as an unclassified medical device, which requires premarket approval or de novo classification. Opponents of the FDA's action expressed their concerns, saying that the FDA is overcautious and paternalistic, which violates consumers' rights and might stifle the consumer genomics field itself, and insisted that the agency should not restrict direct-to-consumer (DTC) genomic testing without empirical evidence of harm. Proponents support the agency's action as protection of consumers from potentially invalid and almost useless information. This action was also significant, since it reflected the FDA's attitude towards medical application of next-generation sequencing techniques. In this review, we followed up on the FDA-23andMe incident and evaluated the problems and prospects for DTC genetic testing.

• Polymer(Korea)
• /
• v.26 no.5
• /
• pp.623-633
• /
• 2002

The flame retardant and thermal properties of ortho-cresol novolac (OCN) and biphenyl epoxy blends containing red-phosphorus were investigated. For five types of compounds designed with the volume ratio of OCN and biphenyl epoxy, thermal properties were analysed by TGA or DTC, and flame retardancy effectiveness was estimated through UL-94V test. While the flame retardant and thermal properties were improved with the content of filler and red-phosphorus, the excessive amount of red-phosphorus caused to deteriorate those properties. Using the blends of OCN/biphenyl rather than pure OCN or biphenyl epoxy as a matrix the flame retardancy of composites could be improved by the synergic effects of high thermal resistance of OCN and intumescent property of biphenyl. The flame retardant me chanism of epoxy compound containing red-phosphorus could be thought of the heat-insulating effect of intumescent char-layer formed in the surface of composites.